{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:57:48Z","timestamp":1787162268970,"version":"build-2736575974"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U01DK062404"],"award-info":[{"award-number":["U01DK062404"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Autosomal dominant polycystic kidney disease (ADPKD) is the most commonly inherited kidney disease. Although children with ADPKD show normal renal function, cyst development is already occurring. In this study, we aimed to identify markers and associated molecular pathways of disease progression in children and young adults with ADPKD. Plasma samples were collected during a 3-year randomized, double-blind, placebo-controlled, phase III clinical trial that was designed to test the efficacy of pravastatin on slowing down ADPKD progression in pediatric patients. Samples from 58 patients were available at baseline and at the 3-year endpoint of the study, respectively. Furthermore, plasma samples from 98 healthy children were used as controls. Metabolomic analysis was performed using liquid chromatography-tandem mass spectrometry and differences in metabolic profiles over time and within study groups were evaluated. While pravastatin therapy led to a decrease in a percent change of total kidney volume (HtTKV) in ADPKD patients, it had minimal effects on metabolite changes. Oxidative stress, endothelial dysfunction, inflammation and immune response were the most affected signaling pathways that distinguished healthy from diseased children. Pathway analysis revealed that metabolites in the arginine metabolism (urea and nitric oxide cycles), asparagine and glutamine metabolism, in the methylation cycle and kynurenine pathway were significantly changed between healthy and children with ADPDK and continued to diverge from the control levels while the disease progressed. Detected metabolite changes were primarily governed by disease progression, and less by pravastatin treatment. Identified metabolic pathways, from arginine and asparagine to kynurenine metabolism could present therapeutic targets and should be further investigated for potential to treat ADPKD progression at an early stage.<\/jats:p>","DOI":"10.1038\/s41598-021-84609-8","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T07:04:44Z","timestamp":1616483084000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Metabolic profiling in children and young adults with autosomal dominant polycystic kidney disease"],"prefix":"10.1038","volume":"11","author":[{"given":"Madhurima M.","family":"Baliga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jost","family":"Klawitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Christians","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Hopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Chonchol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berenice Y.","family":"Gitomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Cadnapaphornchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Klawitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"key":"84609_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00467-016-3364-y","volume":"32","author":"BV Reddy","year":"2017","unstructured":"Reddy, B. V. & Chapman, A. B. The spectrum of autosomal dominant polycystic kidney disease in children and adolescents. Pediatr. Nephrol. 32, 31\u201342. https:\/\/doi.org\/10.1007\/s00467-016-3364-y (2017).","journal-title":"Pediatr. Nephrol."},{"key":"84609_CR2","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/s0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres, V. E., Harris, P. C. & Pirson, Y. Autosomal dominant polycystic kidney disease. Lancet 369, 1287\u20131301. https:\/\/doi.org\/10.1016\/s0140-6736(07)60601-1 (2007).","journal-title":"Lancet"},{"key":"84609_CR3","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1093\/ndt\/gft513","volume":"29","author":"F Rahbari-Oskoui","year":"2014","unstructured":"Rahbari-Oskoui, F., Williams, O. & Chapman, A. Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease. Nephrol. Dial. Transpl. 29, 2194\u20132201. https:\/\/doi.org\/10.1093\/ndt\/gft513 (2014).","journal-title":"Nephrol. Dial. Transpl."},{"key":"84609_CR4","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1681\/ASN.V121194","volume":"12","author":"T Ecder","year":"2001","unstructured":"Ecder, T. & Schrier, R. W. Hypertension in autosomal-dominant polycystic kidney disease: Early occurrence and unique aspects. J. Am. Soc. Nephrol. 12, 194\u2013200 (2001).","journal-title":"J. Am. Soc. Nephrol."},{"key":"84609_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1053\/j.ackd.2010.01.001","volume":"17","author":"AB Chapman","year":"2010","unstructured":"Chapman, A. B., Stepniakowski, K. & Rahbari-Oskoui, F. Hypertension in autosomal dominant polycystic kidney disease. Adv. Chronic Kidney Dis. 17, 153\u2013163. https:\/\/doi.org\/10.1053\/j.ackd.2010.01.001 (2010).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"84609_CR6","doi-asserted-by":"publisher","first-page":"874","DOI":"10.2215\/CJN.11401017","volume":"13","author":"L Massella","year":"2018","unstructured":"Massella, L. et al. Prevalence of hypertension in children with early-stage ADPKD. Clin. J. Am. Soc. Nephrol. 13, 874\u2013883. https:\/\/doi.org\/10.2215\/CJN.11401017 (2018).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"84609_CR7","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1136\/archdischild-2015-310221","volume":"101","author":"M Marlais","year":"2016","unstructured":"Marlais, M. et al. Hypertension in autosomal dominant polycystic kidney disease: A meta-analysis. Arch Dis Child 101, 1142\u20131147. https:\/\/doi.org\/10.1136\/archdischild-2015-310221 (2016).","journal-title":"Arch Dis Child"},{"key":"84609_CR8","unstructured":"Augustyniak-Bartosik, H. et al. The phenotypic characteristics of adult polycystic kidney disease have greater impact on the course of progressive disease than the type of mutation of the polycystin 1 gene. Vol. 17 (2008)."},{"key":"84609_CR9","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1681\/ASN.V8101560","volume":"8","author":"AM Johnson","year":"1997","unstructured":"Johnson, A. M. & Gabow, P. A. Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J. Am. Soc. Nephrol. 8, 1560 (1997).","journal-title":"J. Am. Soc. Nephrol."},{"key":"84609_CR10","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1681\/ASN.2013111184","volume":"25","author":"RW Schrier","year":"2014","unstructured":"Schrier, R. W. et al. Predictors of autosomal dominant polycystic kidney disease progression. J. Am. Soc. Nephrol. 25, 2399\u20132418. https:\/\/doi.org\/10.1681\/ASN.2013111184 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"84609_CR11","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.cct.2011.01.008","volume":"32","author":"MA Cadnapaphornchai","year":"2011","unstructured":"Cadnapaphornchai, M. A. et al. Effect of statin therapy on disease progression in pediatric ADPKD: Design and baseline characteristics of participants. Contemp. Clin. Trials 32, 437\u2013445. https:\/\/doi.org\/10.1016\/j.cct.2011.01.008 (2011).","journal-title":"Contemp. Clin. Trials"},{"key":"84609_CR12","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2215\/CJN.08350813","volume":"9","author":"MA Cadnapaphornchai","year":"2014","unstructured":"Cadnapaphornchai, M. A. et al. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 9, 889\u2013896. https:\/\/doi.org\/10.2215\/CJN.08350813 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"84609_CR13","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s13238-015-0185-x","volume":"6","author":"B Peng","year":"2015","unstructured":"Peng, B., Li, H. & Peng, X. X. Functional metabolomics: From biomarker discovery to metabolome reprogramming. Protein Cell 6, 628\u2013637. https:\/\/doi.org\/10.1007\/s13238-015-0185-x (2015).","journal-title":"Protein Cell"},{"key":"84609_CR14","doi-asserted-by":"publisher","first-page":"F909","DOI":"10.1152\/ajprenal.00722.2009","volume":"298","author":"SL Taylor","year":"2010","unstructured":"Taylor, S. L. et al. A metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic kidney disease. Am. J. Physiol. Renal Physiol. 298, F909-922. https:\/\/doi.org\/10.1152\/ajprenal.00722.2009 (2010).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"84609_CR15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ebiom.2016.01.027","volume":"5","author":"LF Menezes","year":"2016","unstructured":"Menezes, L. F., Lin, C. C., Zhou, F. & Germino, G. G. Fatty acid oxidation is impaired in an orthologous mouse model of autosomal dominant polycystic kidney disease. EBioMedicine 5, 183\u2013192. https:\/\/doi.org\/10.1016\/j.ebiom.2016.01.027 (2016).","journal-title":"EBioMedicine"},{"key":"84609_CR16","doi-asserted-by":"publisher","first-page":"F1855","DOI":"10.1152\/ajprenal.00025.2018","volume":"315","author":"JF Trott","year":"2018","unstructured":"Trott, J. F. et al. Arginine reprogramming in ADPKD results in arginine-dependent cystogenesis. Am. J. Physiol. Renal Physiol. 315, F1855\u2013F1868. https:\/\/doi.org\/10.1152\/ajprenal.00025.2018 (2018).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"84609_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12882-019-1249-6","volume":"20","author":"K Kim","year":"2019","unstructured":"Kim, K., Trott, J. F., Gao, G., Chapman, A. & Weiss, R. H. Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course. BMC Nephrol. 20, 66. https:\/\/doi.org\/10.1186\/s12882-019-1249-6 (2019).","journal-title":"BMC Nephrol."},{"key":"84609_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz121","author":"M Zacchia","year":"2019","unstructured":"Zacchia, M. et al. Proteomics and metabolomics studies exploring the pathophysiology of renal dysfunction in autosomal dominant polycystic kidney disease and other ciliopathies. Nephrol. Dial. Transplant https:\/\/doi.org\/10.1093\/ndt\/gfz121 (2019).","journal-title":"Nephrol. Dial. Transplant"},{"key":"84609_CR19","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.2215\/CJN.11331114","volume":"10","author":"J Klawitter","year":"2015","unstructured":"Klawitter, J. et al. Pravastatin therapy and biomarker changes in children and young adults with autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 10, 1534\u20131541. https:\/\/doi.org\/10.2215\/CJN.11331114 (2015).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"84609_CR20","doi-asserted-by":"publisher","first-page":"e010711","DOI":"10.1161\/JAHA.118.010711","volume":"7","author":"JA Davidson","year":"2018","unstructured":"Davidson, J. A. et al. Metabolomic fingerprinting of infants undergoing cardiopulmonary bypass: Changes in metabolic pathways and association with mortality and cardiac intensive care unit length of stay. J. Am. Heart. Assoc. 7, e010711. https:\/\/doi.org\/10.1161\/JAHA.118.010711 (2018).","journal-title":"J. Am. Heart. Assoc."},{"key":"84609_CR21","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/nprot.2012.024","volume":"7","author":"M Yuan","year":"2012","unstructured":"Yuan, M., Breitkopf, S. B., Yang, X. & Asara, J. M. A positive\/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nat. Protoc. 7, 872\u2013881. https:\/\/doi.org\/10.1038\/nprot.2012.024 (2012).","journal-title":"Nat. Protoc."},{"key":"84609_CR22","doi-asserted-by":"publisher","first-page":"W486","DOI":"10.1093\/nar\/gky310","volume":"46","author":"J Chong","year":"2018","unstructured":"Chong, J. et al. MetaboAnalyst 4.0: Towards more transparent and integrative metabolomics analysis. Nucleic Acids Res. 46, W486\u2013W494. https:\/\/doi.org\/10.1093\/nar\/gky310 (2018).","journal-title":"Nucleic Acids Res."},{"key":"84609_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/10408363.2018.1427041","volume":"55","author":"E den Bakker","year":"2018","unstructured":"den Bakker, E., Gemke, R. & Bokenkamp, A. Endogenous markers for kidney function in children: A review. Crit. Rev. Clin. Lab. Sci. 55, 163\u2013183. https:\/\/doi.org\/10.1080\/10408363.2018.1427041 (2018).","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"84609_CR24","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/MNH.0b013e3282fb77f2","volume":"17","author":"DF Work","year":"2008","unstructured":"Work, D. F. & Schwartz, G. J. Estimating and measuring glomerular filtration rate in children. Curr. Opin. Nephrol. Hypertens. 17, 320\u2013325. https:\/\/doi.org\/10.1097\/MNH.0b013e3282fb77f2 (2008).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"84609_CR25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000448695","volume":"44","author":"KL Nowak","year":"2016","unstructured":"Nowak, K. L., Cadnapaphornchai, M. A., Chonchol, M. B., Schrier, R. W. & Gitomer, B. Long-term outcomes in patients with very-early onset autosomal dominant polycystic kidney disease. Am. J. Nephrol. 44, 171\u2013178. https:\/\/doi.org\/10.1159\/000448695 (2016).","journal-title":"Am. J. Nephrol."},{"key":"84609_CR26","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1111\/j.1523-1755.2005.00678.x","volume":"68","author":"AA Shamshirsaz","year":"2005","unstructured":"Shamshirsaz, A. A. et al. Autosomal-dominant polycystic kidney disease in infancy and childhood: Progression and outcome. Kidney Int. 68, 2218\u20132224. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00678.x (2005).","journal-title":"Kidney Int."},{"key":"84609_CR27","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/hr.2010.113","volume":"33","author":"T Toyohara","year":"2010","unstructured":"Toyohara, T. et al. Metabolomic profiling of uremic solutes in CKD patients. Hypertens. Res. 33, 944\u2013952. https:\/\/doi.org\/10.1038\/hr.2010.113 (2010).","journal-title":"Hypertens. Res."},{"key":"84609_CR28","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s00216-016-0165-x","volume":"409","author":"J Boelaert","year":"2017","unstructured":"Boelaert, J. et al. Metabolic profiling of human plasma and urine in chronic kidney disease by hydrophilic interaction liquid chromatography coupled with time-of-flight mass spectrometry: A pilot study. Anal. Bioanal. Chem. 409, 2201\u20132211. https:\/\/doi.org\/10.1007\/s00216-016-0165-x (2017).","journal-title":"Anal. Bioanal. Chem."},{"key":"84609_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2215\/CJN.06000613","volume":"9","author":"F Duranton","year":"2014","unstructured":"Duranton, F. et al. Plasma and urinary amino acid metabolomic profiling in patients with different levels of kidney function. Clin. J. Am. Soc. Nephrol. 9, 37\u201345. https:\/\/doi.org\/10.2215\/CJN.06000613 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"84609_CR30","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1046\/j.1523-1755.2003.00924.x","volume":"63","author":"R Vanholder","year":"2003","unstructured":"Vanholder, R. et al. Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int. 63, 1934\u20131943. https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00924.x (2003).","journal-title":"Kidney Int."},{"key":"84609_CR31","doi-asserted-by":"publisher","first-page":"e71199","DOI":"10.1371\/journal.pone.0071199","volume":"8","author":"HA Mutsaers","year":"2013","unstructured":"Mutsaers, H. A. et al. Optimized metabolomic approach to identify uremic solutes in plasma of stage 3\u20134 chronic kidney disease patients. PLoS ONE 8, e71199. https:\/\/doi.org\/10.1371\/journal.pone.0071199 (2013).","journal-title":"PLoS ONE"},{"key":"84609_CR32","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41581-019-0111-1","volume":"15","author":"SK Nigam","year":"2019","unstructured":"Nigam, S. K. & Bush, K. T. Uraemic syndrome of chronic kidney disease: Altered remote sensing and signalling. Nat. Rev. Nephrol. 15, 301\u2013316. https:\/\/doi.org\/10.1038\/s41581-019-0111-1 (2019).","journal-title":"Nat. Rev. Nephrol."},{"key":"84609_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/toxins10010033","author":"R Vanholder","year":"2018","unstructured":"Vanholder, R., Pletinck, A., Schepers, E. & Glorieux, G. Biochemical and clinical impact of organic uremic retention solutes: A comprehensive update. Toxins https:\/\/doi.org\/10.3390\/toxins10010033 (2018).","journal-title":"Toxins"},{"key":"84609_CR34","doi-asserted-by":"publisher","first-page":"6770","DOI":"10.1073\/pnas.93.13.6770","volume":"93","author":"Y Xia","year":"1996","unstructured":"Xia, Y., Dawson, V. L., Dawson, T. M., Snyder, S. H. & Zweier, J. L. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc. Natl. Acad. Sci. USA 93, 6770\u20136774. https:\/\/doi.org\/10.1073\/pnas.93.13.6770 (1996).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"84609_CR35","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/cvr\/cvt036","volume":"98","author":"J Pernow","year":"2013","unstructured":"Pernow, J. & Jung, C. Arginase as a potential target in the treatment of cardiovascular disease: Reversal of arginine steal?. Cardiovasc. Res. 98, 334\u2013343. https:\/\/doi.org\/10.1093\/cvr\/cvt036 (2013).","journal-title":"Cardiovasc. Res."},{"key":"84609_CR36","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/ni.3421","volume":"17","author":"LA Monticelli","year":"2016","unstructured":"Monticelli, L. A. et al. Arginase 1 is an innate lymphoid-cell-intrinsic metabolic checkpoint controlling type 2 inflammation. Nat. Immunol. 17, 656\u2013665. https:\/\/doi.org\/10.1038\/ni.3421 (2016).","journal-title":"Nat. Immunol."},{"key":"84609_CR37","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41586-018-0697-7","volume":"563","author":"L Poillet-Perez","year":"2018","unstructured":"Poillet-Perez, L. et al. Autophagy maintains tumour growth through circulating arginine. Nature 563, 569\u2013573. https:\/\/doi.org\/10.1038\/s41586-018-0697-7 (2018).","journal-title":"Nature"},{"key":"84609_CR38","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1681\/ASN.2018010074","volume":"29","author":"Y Yang","year":"2018","unstructured":"Yang, Y. et al. Interactions between macrophages and cyst-lining epithelial cells promote kidney cyst growth in pkd1-deficient mice. J. Am. Soc. Nephrol. 29, 2310\u20132325. https:\/\/doi.org\/10.1681\/ASN.2018010074 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"84609_CR39","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2217\/bmm-2017-0102","volume":"11","author":"A Synakiewicz","year":"2017","unstructured":"Synakiewicz, A. et al. Amino acid profiles as potential biomarkers for pediatric cancers: A preliminary communication. Biomark. Med. 11, 619\u2013627. https:\/\/doi.org\/10.2217\/bmm-2017-0102 (2017).","journal-title":"Biomark. Med."},{"key":"84609_CR40","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nature10602","volume":"481","author":"CM Metallo","year":"2011","unstructured":"Metallo, C. M. et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481, 380\u2013384. https:\/\/doi.org\/10.1038\/nature10602 (2011).","journal-title":"Nature"},{"key":"84609_CR41","doi-asserted-by":"publisher","DOI":"10.2174\/0929867326666190416165004","author":"JM Mates","year":"2019","unstructured":"Mates, J. M. et al. Metabolic reprogramming of cancer by chemicals that target glutaminase isoenzymes. Curr. Med. Chem. https:\/\/doi.org\/10.2174\/0929867326666190416165004 (2019).","journal-title":"Curr. Med. Chem."},{"key":"84609_CR42","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.semcdb.2019.05.012","volume":"98","author":"JM Mates","year":"2020","unstructured":"Mates, J. M., Di Paola, F. J., Campos-Sandoval, J. A., Mazurek, S. & Marquez, J. Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer. Semin. Cell Dev. Biol. 98, 34\u201343. https:\/\/doi.org\/10.1016\/j.semcdb.2019.05.012 (2020).","journal-title":"Semin. Cell Dev. Biol."},{"key":"84609_CR43","doi-asserted-by":"publisher","first-page":"19952","DOI":"10.1074\/jbc.R117.819060","volume":"292","author":"CL Lomelino","year":"2017","unstructured":"Lomelino, C. L., Andring, J. T., McKenna, R. & Kilberg, M. S. Asparagine synthetase: Function, structure, and role in disease. J. Biol. Chem. 292, 19952\u201319958. https:\/\/doi.org\/10.1074\/jbc.R117.819060 (2017).","journal-title":"J. Biol. Chem."},{"key":"84609_CR44","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/229168a0","volume":"229","author":"D Crowther","year":"1971","unstructured":"Crowther, D. l-asparaginase and human malignant disease. Nature 229, 168\u2013171. https:\/\/doi.org\/10.1038\/229168a0 (1971).","journal-title":"Nature"},{"key":"84609_CR45","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41467-018-03036-y","volume":"9","author":"EM Flowers","year":"2018","unstructured":"Flowers, E. M. et al. Lkb1 deficiency confers glutamine dependency in polycystic kidney disease. Nat. Commun. 9, 814. https:\/\/doi.org\/10.1038\/s41467-018-03036-y (2018).","journal-title":"Nat. Commun."},{"key":"84609_CR46","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s42003-018-0200-x","volume":"1","author":"C Podrini","year":"2018","unstructured":"Podrini, C. et al. Dissection of metabolic reprogramming in polycystic kidney disease reveals coordinated rewiring of bioenergetic pathways. Commun. Biol. 1, 194. https:\/\/doi.org\/10.1038\/s42003-018-0200-x (2018).","journal-title":"Commun. Biol."},{"key":"84609_CR47","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.atherosclerosis.2008.10.002","volume":"204","author":"K Pawlak","year":"2009","unstructured":"Pawlak, K., Brzosko, S., Mysliwiec, M. & Pawlak, D. Kynurenine, quinolinic acid\u2013the new factors linked to carotid atherosclerosis in patients with end-stage renal disease. Atherosclerosis 204, 561\u2013566. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2008.10.002 (2009).","journal-title":"Atherosclerosis"},{"key":"84609_CR48","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/ndt\/gfn739","volume":"24","author":"JC Schefold","year":"2009","unstructured":"Schefold, J. C. et al. Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: A possible link between chronic inflammation and uraemic symptoms. Nephrol. Dial. Transplant. 24, 1901\u20131908. https:\/\/doi.org\/10.1093\/ndt\/gfn739 (2009).","journal-title":"Nephrol. Dial. Transplant."},{"key":"84609_CR49","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1681\/ASN.2012101006","volume":"24","author":"EP Rhee","year":"2013","unstructured":"Rhee, E. P. et al. A combined epidemiologic and metabolomic approach improves CKD prediction. J. Am. Soc. Nephrol. 24, 1330\u20131338. https:\/\/doi.org\/10.1681\/ASN.2012101006 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"84609_CR50","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.2215\/CJN.02560317","volume":"12","author":"ME Grams","year":"2017","unstructured":"Grams, M. E. et al. Metabolomic alterations associated with cause of CKD. Clin. J. Am. Soc. Nephrol. 12, 1787\u20131794. https:\/\/doi.org\/10.2215\/CJN.02560317 (2017).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"84609_CR51","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2215\/CJN.05610519","volume":"15","author":"K Wang","year":"2020","unstructured":"Wang, K. et al. Alterations of proximal tubular secretion in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 15, 80\u201388. https:\/\/doi.org\/10.2215\/CJN.05610519 (2020).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"84609_CR52","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-018-0644-y","volume":"11","author":"M Liu","year":"2018","unstructured":"Liu, M. et al. Targeting the IDO1 pathway in cancer: From bench to bedside. J. Hematol. Oncol. 11, 100. https:\/\/doi.org\/10.1186\/s13045-018-0644-y (2018).","journal-title":"J. Hematol. Oncol."},{"key":"84609_CR53","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","volume":"18","author":"M Platten","year":"2019","unstructured":"Platten, M., Nollen, E. A. A., Rohrig, U. F., Fallarino, F. & Opitz, C. A. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat. Rev. Drug Discov. 18, 379\u2013401. https:\/\/doi.org\/10.1038\/s41573-019-0016-5 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"84609_CR54","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1046\/j.1471-4159.1997.69010290.x","volume":"69","author":"JBP Gramsbergen","year":"2002","unstructured":"Gramsbergen, J. B. P. et al. Brain-specific modulation of kynurenic acid synthesis in the rat. J. Neurochem. 69, 290\u2013298. https:\/\/doi.org\/10.1046\/j.1471-4159.1997.69010290.x (2002).","journal-title":"J. Neurochem."},{"key":"84609_CR55","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1681\/ASN.2013121283","volume":"26","author":"L Dou","year":"2015","unstructured":"Dou, L. et al. The cardiovascular effect of the uremic solute indole-3 acetic acid. J. Am. Soc. Nephrol. 26, 876\u2013887. https:\/\/doi.org\/10.1681\/ASN.2013121283 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"84609_CR56","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nm.3092","volume":"19","author":"I Rowe","year":"2013","unstructured":"Rowe, I. et al. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat. Med. 19, 488\u2013493. https:\/\/doi.org\/10.1038\/nm.3092 (2013).","journal-title":"Nat. Med."},{"key":"84609_CR57","doi-asserted-by":"publisher","first-page":"109495","DOI":"10.1016\/j.cellsig.2019.109495","volume":"67","author":"C Podrini","year":"2020","unstructured":"Podrini, C., Cassina, L. & Boletta, A. Metabolic reprogramming and the role of mitochondria in polycystic kidney disease. Cell Signal 67, 109495. https:\/\/doi.org\/10.1016\/j.cellsig.2019.109495 (2020).","journal-title":"Cell Signal"},{"key":"84609_CR58","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41581-018-0051-1","volume":"14","author":"V Padovano","year":"2018","unstructured":"Padovano, V., Podrini, C., Boletta, A. & Caplan, M. J. Metabolism and mitochondria in polycystic kidney disease research and therapy. Nat. Rev. Nephrol. 14, 678\u2013687. https:\/\/doi.org\/10.1038\/s41581-018-0051-1 (2018).","journal-title":"Nat. Rev. Nephrol."},{"key":"84609_CR59","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/nature20165","volume":"540","author":"PA Tyrakis","year":"2016","unstructured":"Tyrakis, P. A. et al. S-2-hydroxyglutarate regulates CD8(+) T-lymphocyte fate. Nature 540, 236\u2013241. https:\/\/doi.org\/10.1038\/nature20165 (2016).","journal-title":"Nature"},{"key":"84609_CR60","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.trecan.2017.12.005","volume":"4","author":"D Ye","year":"2018","unstructured":"Ye, D., Guan, K. L. & Xiong, Y. Metabolism, activity, and targeting of D- and L-2-hydroxyglutarates. Trends Cancer 4, 151\u2013165. https:\/\/doi.org\/10.1016\/j.trecan.2017.12.005 (2018).","journal-title":"Trends Cancer"},{"key":"84609_CR61","doi-asserted-by":"publisher","first-page":"F492","DOI":"10.1152\/ajprenal.00238.2015","volume":"309","author":"VJ Hwang","year":"2015","unstructured":"Hwang, V. J. et al. The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate. Am. J. Physiol. Renal Physiol. 309, F492-498. https:\/\/doi.org\/10.1152\/ajprenal.00238.2015 (2015).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"84609_CR62","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.biochi.2018.06.009","volume":"152","author":"RE Silva","year":"2018","unstructured":"Silva, R. E. et al. Predictive metabolomic signatures of end-stage renal disease: A multivariate analysis of population-based data. Biochimie 152, 14\u201330. https:\/\/doi.org\/10.1016\/j.biochi.2018.06.009 (2018).","journal-title":"Biochimie"},{"key":"84609_CR63","doi-asserted-by":"publisher","first-page":"c38","DOI":"10.1159\/000245068","volume":"114","author":"M Busch","year":"2010","unstructured":"Busch, M. et al. Vitamin B6 metabolism in chronic kidney disease\u2013relation to transsulfuration, advanced glycation and cardiovascular disease. Nephron Clin. Pract. 114, c38-46. https:\/\/doi.org\/10.1159\/000245068 (2010).","journal-title":"Nephron Clin. Pract."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84609-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84609-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84609-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:50:24Z","timestamp":1670028624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84609-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["84609"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-84609-8","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.739811680.793584372","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,23]]},"assertion":[{"value":"6 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6629"}}